Tromsø, Norway, 20[th] May 2020 - Biotec Pharmacon (OSE: Biotec) announces that
its subsidiary, ArcticZymes AS, has been granted up to NOK 1.65 million by
Innovation Norway for a project to increase the manufacturing scale of its SAN
-HQ enzyme

ArcticZymes' Salt Active Nuclease High Quality (SAN-HQ) enzyme offers gene
therapy and vaccine customers a more cost effective and technically superior
solution for removing contaminating DNA during the manufacturing process of
therapeutic viruses. The project will accelerate ongoing efforts to scale
production capacity and is estimated to be completed within 8-10 months.

The company entered the therapeutic segment with its SAN portfolio in 2016.
Since then it has rapidly grown its customer base, and in 2019 sales revenues
accounted for 25% of total sales. Customers initially start out purchasing small
quantities of SAN-HQ, and then quickly scale their manufacturing in order to
achieve the batch sizes required for pre-commercial and future commercial
requirements. Furthermore, supply of SAN-HQ has the potential to be expanded
into our partners developing viral based vaccines against COVID-19.

The growing demand of the SAN-HQ enzyme requires a timely effort to scale the
manufacturing of the enzyme in order to seamlessly cater for longer-term
customer supply.

ArcticZymes AS, CEO, Jethro Holter said:

"ArcticZymes has quickly achieved a strong commercial foothold in therapeutics
by offering gene therapy and vaccine manufacturers unique enzyme technologies to
streamline their production processes. This project will ensure that ArcticZymes
accelerates its efforts to scale SAN-HQ manufacturing to satisfy growing
commercial demand. We are grateful to Innovation Norway for supporting the
project and recognizing its underlying value. The funding enables ArcticZymes to
invest in more resources and fast track its endeavours to further scale SAN-HQ
production and expand its support towards COVID-19 initiatives."

Thomas Stien, Financial advisor, Innovation Norway, added:

"As part of the Norwegian government's efforts to limit the effects of the
coronavirus eruption, Innovation Norway has been given an increased limit for
innovation grants aimed at companies with growth ambitions. The grant will help
companies continue to pursue good innovation projects - or facilitate new ones.

This project shows that ArcticZymes sees the opportunity in the situation and
prepares to deal with the challenges in a longer perspective - both to
strengthen the company's competitiveness and to prepare for further growth."

-ENDS-

For more information, please contact:

Dr Jethro Holter, CEO            Tel: +47 46 85 91 46
                       Email: Jethro.Holter@biotec.no

About Biotec Pharmacon ASA

Biotec Pharmacon is a Norwegian life sciences company focused on specialized,
novel enzyme and immunomodulating beta-glucan technology.

The Biotec Pharmacon Group is creating value from innovation in life science
markets via its subsidiaries, ArcticZymes and Biotec BetaGlucans. Its
technologies capitalize on more than three decades of world-class research at
the Arctic University of Tromsø to offer niche and high-tech products in several
biotech segments.

For more information, please visit the website: www.biotec.no.

About ArcticZymes

ArcticZymes develops, produces and markets novel recombinant enzymes for use in
molecular research, In Vitro Diagnostics (IVD) and therapeutics.

The Company focuses on novel and high-quality enzyme technologies in growth
markets where rapid technological developments are creating a strong demand for
new and improved enzymes. Some of its enzymes' unique features include heat
lability and activity in challenging environments as well as customized,
engineered novel features which can be integrated to power the technologies of
commercial partners.

All ArcticZymes products are ISO13485 certified.

For more information, please visit: www.arcticzymes.com